ClinicalTrials.gg
RecruitingNCT06672939Updated Nov 4, 2026

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

A Phase 3 interventional study of Orforglipron and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Recruiting at 34 sites in 6 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Planned enrollment
15th of 22
150 · median 324
Started
2024
with 5 others
Phase 3
14 of 22
3 open now
Registered
13th of 22
by date
Lead sponsor
21 of 22
Eli Lilly and Company

Among the 22 studies testing orforglipron in Obesity, this one is the 15th largest by planned enrollment, is one of 6 that started in 2024, is one of 14 in phase 3, and was the 13th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months.

Participants who have completed the primary PW01 study (including the 4-week safety follow-up period) will have the opportunity to receive an additional 156 weeks of treatment with orforglipron as well as continuing the lifestyle intervention.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

J4M-MC-PWMP

  • Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.
  • Obesity as defined by equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart [CDC-NCHS, 2022]); OR
  • Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,

    • hypertension
    • type 2 diabetes (T2D)
    • prediabetes
    • dyslipidemia
    • obstructive sleep apnea
    • metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated steatotic liver disease (MASLD)

Exclusion criteria

Exclusion Criteria:

J4M-MC-PW01

  • Prepubertal (Tanner stage 1)
  • Have a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kilograms (kg) (11 pounds) within 90 days before screening

J4M-MC-PWMP

  • Have undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:

    • gastric bypass
    • sleeve gastrectomy
    • restrictive bariatric surgery, such as Lap-Band® gastric banding, or
    • any other procedure intended to result in weight reduction.
  • Have a diagnosis that is a secondary cause of obesity or have a history of abrupt onset of obesity suggesting a secondary cause, such as hypothalamic, monogenetic, syndromic, or endocrine causes.
  • Have type 1 diabetes or history of ketoacidosis, or hyperosmolar state.
  • Have >9.0% (75 mmol/mol) as measured by central laboratory at screening.
  • Have a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Orforglipron

    Participants will receive orforglipron orally

    Drug: Orforglipron

  • Placebo comparator
    Placebo

    Participants will receive placebo orally

    Drug: Placebo

Interventions

  • Administered orally

    Also known as: LY3502970

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 72

Secondary outcomes

  1. Change from Baseline in BMI

    Time frame: Baseline, Week 72

  2. Change from Baseline in Body Weight

    Time frame: Baseline, Week 72

  3. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 72

  4. Change from Baseline in Body Weight Percentile

    Based on sex- and age-specific growth charts

    Time frame: Baseline, Week 72

  5. Change in Impact of Weight on Quality of Life (IWQOL)-Kids Total and Domain Scores

    The IWQOL-Kids is a validated, 27-item, patient reported outcomes instrument that assesses weight-related quality of life for youth aged 11 to 19 years in 4 domains: * physical comfort (6 items) * body esteem (9 items) * social life (6 items), and * family relations (6 items). It has a recall period of "the past 7 days." All items are rated on a 5-point truth scale ("always true" to "never true"). The 4-domain scores and total score range from 0 to 100, with higher scores indicating better quality of life.

    Time frame: Baseline, Week 72

  6. Change from Baseline in Systolic Blood Pressure

    Time frame: Baseline, Week 72

  7. Change from Baseline in Diastolic Blood Pressure

    Time frame: Baseline, Week 72

  8. Percent Change from Baseline in Total Cholesterol

    Time frame: Baseline, Week 72

  9. Change from Baseline in Fasting Glucose

    Time frame: Baseline, Week 72

  10. Percent Change from Baseline in Fasting Insulin

    Time frame: Baseline, Week 72

  11. Percent Change from Baseline in Total Body Fat Mass as Determined by Dual-Energy X-Ray Absorptiometry (DXA)

    Time frame: Baseline, Week 72

  12. Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Orforglipron

    Time frame: Baseline, Week 72

07

Study locations

8 of 34 sites recruiting
  • Carey Chronis MD Pediatric, Infant and Adolescent Medicine
    Oxnard, California 93030, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Children's Healthcare of Atlanta - Center for Advanced Pediatrics
    Atlanta, Georgia 30329, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Velocity Clinical Research
    Lafayette, Louisiana 70508, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sundance Clinical Research
    St Louis, Missouri 63141-7068, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Lucas Research, Inc.
    Morehead City, North Carolina 28557, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Childrens Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Vanderbilt Health One Hundred Oaks
    Nashville, Tennessee 37212, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Dynamed Clinical Research, LP d/b/a DM Clinical Research
    Houston, Texas 77065, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • La Providence Pediatrics Clinic - Chemidox Clinical Trials
    Houston, Texas 77071-1008, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Martin Diagnostic Clinic
    Tomball, Texas 77375-3332, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Shamir Medical Center
    Beer Jacob, 73100, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Shaare Zedek Medical Center
    Jerusalem, 9013102, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sheba Medical Center
    Ramat Gan, 52621, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero Universitaria Meyer
    Florence, 50139, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero Universitaria Maggiore della Carità
    Novara, 28100, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento
    Verona, 37126, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Saitama Medical University Hospital
    Iruma-Gun, 350-0495, Japan
    Recruiting
    • · Contact81120023812
    • Toru Kikuchi · Principal investigator
  • Isesaki Municipal Hospital
    Isesaki-shi, 372-0817, Japan
    Recruiting
    • · Contact81120023812
    • Yoko Takano · Principal investigator
  • University Hospital,Kyoto Prefectural University of Medicine
    Kawaramachidori, Kamigyo-ku, Kyoto-city, 602-8566, Japan
    Not yet recruiting
    • · Contact81120023812
    • Satoru Sugimoto · Principal investigator
  • Tokyo Medical Center
    Meguro-Ku, 152-0021, Japan
    Recruiting
    • · Contact81120023812
    • Masashi Miharu · Principal investigator
  • Shiga General Hospital
    Moriyama, 524-8524, Japan
    Recruiting
    • · Contact81120023812
    • Katsuyuki Matsui · Principal investigator
  • Nara Prefecture General Medical Center
    Nara, 630-8054, Japan
    Recruiting
    • · Contact81120023812
    • Sayaka Yoshida · Principal investigator
  • Osaka City General Hospital
    Osaka, 534-0021, Japan
    Recruiting
    • · Contact81120023812
    • Jun Mori · Principal investigator
  • Sagaekiminami Clinic
    Saga, 840-0801, Japan
    Recruiting
    • · Contact81120023812
    • Tateo Kuno · Principal investigator
  • Shikoku Medical Center for Children and Adults
    Zentsujichó, 765-8507, Japan
    Recruiting
    • · Contact81120023812
    • Takafumi Okada · Principal investigator
  • Krakowskie Centrum Medyczne - FutureMeds
    Krakow, 31-501, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • FutureMeds - Targowek
    Warsaw, 03-291, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instytut Diabetologii - Warsaw
    Warszewo, 2117, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • FutureMeds sp. z o. o.
    Wroclaw, 53-673, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Barnsley Hospital NHS Foundation Trust
    Barnsley, S75 2EP, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ninewells Hospital
    Dundee, DD1 9SY, United Kingdom
    Not yet recruiting
    • · Contact(44138) 238-8385
    • Nicholas Conway · Principal investigator
  • Hull Royal Infirmary
    Hull, HU3 2JZ, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2027, 37 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 37 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 4, 2024
StartActual
Nov 18, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Jan 2031
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06672939
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Nov 18, 2024
Primary completion
Dec 2027 (estimated)
Completion
Jan 2031 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion